ClinicalTrials.gg
CompletedNCT06011811Updated Feb 18, 2026

Cluster Headache Treatment Survey

An observational study in Cluster Headache, sponsored by The University of Texas Health Science Center, Houston. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by The University of Texas Health Science Center, Houston · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,487
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to survey patients with cluster headache about treatment effectiveness and their views on treatments. Participants will complete one brief questionnaire online.

02

Conditions studied

  • Cluster Headache

Browse trials for

03

In context

Cluster Headache

123 studies on the registry are indexed under Cluster Headache; 26 are open to participants now.

This study's enrollment of 2,487 is above the median of 68 across 32 observational studies indexed under Cluster Headache.

Browse Cluster Headache studies →

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 897 studies on the registry; 214 are open to participants now.

Of its 173 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population is patients with episodic or chronic cluster headache that has been diagnosed by a health care professional. The cluster headache diagnosis will be verified via the survey using a validated cluster headache diagnostic screen.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with episodic or chronic cluster headache that has been diagnosed by a health care professional (no documentation is needed, participant must simply state that he or she has been diagnosed)

Exclusion criteria

Exclusion Criteria:

  • Unable to speak English (the survey is only in English)
  • Unable to use a computer to take the online survey
  • Unable to provide consent
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,487 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients with episodic or chronic cluster headache

    Patients with a diagnosis of episodic or chronic cluster headache, as diagnosed by a health care professional and to be confirmed by questions on the study survey.

06

What researchers measure

Primary outcomes

  1. Effectiveness of cluster headache treatment as assessed by a survey

    Time frame: at the time of survey completion, expected to be 6-12 months

Secondary outcomes

  1. Opinions on new cluster headache treatment as assessed by a survey

    Time frame: at the time of survey completion, expected to be 6-12 months

07

Study locations

1 site
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jun 2025, 23 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2023
First posted
Aug 25, 2023
StartActual
Jun 29, 2023
Primary completionActual
Jun 28, 2025
CompletionActual
Jun 28, 2025
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06011811
Collaborators
Clusterbusters, Inc.
Responsible party
Mark J Burish (Associate Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Aug 25, 2023
Start date
Jun 29, 2023
Primary completion
Jun 28, 2025
Completion
Jun 28, 2025
Last update
Feb 18, 2026

Study contacts

Mark J Burish, MD, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion